STAT+: Element Biosciences launches table-top sequencer capable of $100 genome

The FDA has refused to review Moderna's application for its mRNA influenza vaccine, marking a significant setback for the company, which has been recognized for its leadership in mRNA technology, particularly during the COVID-19 pandemic. This refusal has been characterized as a major blow to Moderna and raises concerns about the FDA's overall approach to vaccine approvals. The decision reflects a trend towards more stringent scrutiny of vaccine applications compared to previous years (Stat News, Ars Technica). Vinay Prasad, a notable figure in the FDA's decision-making process, reportedly overruled career FDA scientists in rejecting the application. This action has sparked discussions among pediatricians and healthcare professionals regarding the agency's stance on vaccines. The implications of the FDA's decision may extend beyond Moderna, potentially influencing the overall landscape of vaccine development and approval processes within the agency (Stat News, Stat News). The refusal to review the flu vaccine application has raised concerns about public trust in vaccine safety and efficacy. Stakeholders are closely monitoring the FDA's future actions and policies regarding vaccine approvals as the agency navigates challenges in the regulatory processes involved. The situation remains dynamic, with ongoing scrutiny of the FDA's regulatory landscape for vaccines (Stat News, Stat News). Overall, the FDA's decision not to review Moderna's application signifies a pivotal moment in the regulatory landscape for vaccines, highlighting the increased scrutiny that vaccine applications may face moving forward. This development has prompted discussions among various stakeholders in the healthcare and biotech sectors (Stat News, Stat News).